Kelly Poth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kelly Poth has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Anthony Donsante
Department of Neurosurgery, Emory University, Atlanta, GA, USA
1 shared publication Nicholas M Boulis
Department of Neurosurgery, Emory University, Atlanta, Georgia, USA
1 shared publication- Nicholas M. Boulis
Department of Neurosurgery, Emory University School of Medicine, Atlanta, USA
1 shared publication Pavlos Texakalidis
Department of Neurosurgery, Emory University, Atlanta, Georgia, USA
1 shared publication- Roy Raheb Khelo
Department of Neurosurgery, Emory University School of Medicine, Atlanta
1 shared publication
Latest Publications
- 30 July 2025
- Published by Springer Nature in Molecular Diagnosis & Therapy
- p. 1-7
The Future of Chemogenetics for the Treatment of Spasticity
The management of spasticity poses a significant challenge for both physicians and patients. This condition, often characterized by increased muscle tone, clonus, and muscle spasms, can be painful, disrupt daily activities, and increases the risk of injuries. First-line treatment for spasticity includes oral medications, such as baclofen, but these drugs can have significant side effects due to inhibitory effects on neural circuits, such as drowsiness and dizziness. Surgical approaches can be applied to patients for whom oral medications fail. However, these treatments can have life-threatening side effects or are irreversible. An emerging technology, chemogenetics, has the potential to provide targeted relief of spasticity, combining a non-destructive surgical approach with the convenience of an oral medication. This Current Opinion describes the current treatment approaches for spasticity, the pathophysiology of this condition, the current state of chemogenetics, and how this technology may be applied to patients with poorly controlled spasticity. Although the use of this approach is at an early developmental stage, we believe that it shows great promise.
- 30 July 2025
- Published by Springer Nature in Molecular Diagnosis & Therapy
- p. 1-7
The Future of Chemogenetics for the Treatment of Spasticity
The management of spasticity poses a significant challenge for both physicians and patients. This condition, often characterized by increased muscle tone, clonus, and muscle spasms, can be painful, disrupt daily activities, and increases the risk of injuries. First-line treatment for spasticity includes oral medications, such as baclofen, but these drugs can have significant side effects due to inhibitory effects on neural circuits, such as drowsiness and dizziness. Surgical approaches can be applied to patients for whom oral medications fail. However, these treatments can have life-threatening side effects or are irreversible. An emerging technology, chemogenetics, has the potential to provide targeted relief of spasticity, combining a non-destructive surgical approach with the convenience of an oral medication. This Current Opinion describes the current treatment approaches for spasticity, the pathophysiology of this condition, the current state of chemogenetics, and how this technology may be applied to patients with poorly controlled spasticity. Although the use of this approach is at an early developmental stage, we believe that it shows great promise.
- Open Access
- 29 April 2021
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 89 (2) , 185-195
Chemogenetics: Beyond Lesions and Electrodes
The field of chemogenetics has rapidly expanded over the last decade, and engineered receptors are currently utilized in the lab to better understand molecular interactions in the nervous system. We propose that chemogenetic receptors can be used for far more than investigational purposes. The potential benefit of adding chemogenetic neuromodulation to the current neurosurgical toolkit is substantial. There are several conditions currently treated surgically, electrically, and pharmacologically in clinic, and this review highlights how chemogenetic neuromodulation could improve patient outcomes over current neurosurgical techniques. We aim to emphasize the need to take these techniques from bench to bedside.
- 29 April 2021
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 89 (2) , 185-195
Open AccessChemogenetics: Beyond Lesions and Electrodes
The field of chemogenetics has rapidly expanded over the last decade, and engineered receptors are currently utilized in the lab to better understand molecular interactions in the nervous system. We propose that chemogenetic receptors can be used for far more than investigational purposes. The potential benefit of adding chemogenetic neuromodulation to the current neurosurgical toolkit is substantial. There are several conditions currently treated surgically, electrically, and pharmacologically in clinic, and this review highlights how chemogenetic neuromodulation could improve patient outcomes over current neurosurgical techniques. We aim to emphasize the need to take these techniques from bench to bedside.